ZVRA – zevra therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Zevra Therapeutics Announces U.S. Commercial Availability of MIPLYFFA™ (arimoclomol) for Treatment of Niemann-Pick Disease Type C
Zevra Therapeutics, Inc. (NASDAQ: ZVRA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
Zevra Therapeutics, Inc. (NASDAQ: ZVRA) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $25.00 to $23.00. They now have a "buy" rating on the stock.
Zevra Therapeutics Inc (ZVRA) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst ... [Yahoo! Finance]
Zevra Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Updates [Yahoo! Finance]
Form SCHEDULE 13G/A ZEVRA THERAPEUTICS, INC. Filed by: Nantahala Capital Management, LLC
Form SC 13G ZEVRA THERAPEUTICS, INC. Filed by: Woodline Partners LP
Form 10-Q ZEVRA THERAPEUTICS, INC. For: Sep 30
Form SC 13G/A ZEVRA THERAPEUTICS, INC. Filed by: VANGUARD GROUP INC
Form 8-K ZEVRA THERAPEUTICS, INC. For: Nov 12
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.